Sign In
Buy GNMSF
$232.50
+0.160 (+0.0688%)
At Close: Jun 03, 2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:45pm, Tuesday, 18'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increas
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:45pm, Wednesday, 12'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02:50pm, Tuesday, 11'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, t
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
12:51pm, Wednesday, 05'th Jun 2024
Media Release COPENHAGEN, Denmark; June 05, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate
Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, tisotumab vedotin, an antibody-drug conjuga
Genmab Completes Acquisition of ProfoundBio
11:10am, Tuesday, 21'st May 2024
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-gener
Genmab Completes Acquisition of ProfoundBio
11:06am, Tuesday, 21'st May 2024
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinata
Passing of Genmab A/S' Annual General Meeting
11:13am, Wednesday, 13'th Mar 2024
Company Announcement At Genmab A/S' Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approved Discharge was given to the Board of Directors and the Executive Manage
Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript
04:17pm, Wednesday, 14'th Feb 2024
Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
05:33pm, Monday, 04'th Sep 2023
Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall sur
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ce
Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript
05:58pm, Thursday, 03'rd Aug 2023
Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief D
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE™ NHL-1 clinic
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
02:00am, Monday, 17'th Apr 2023
Media Release COPENHAGEN, Denmark; April 1 7 , 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibod
